Bordeaux-based Synapse Medicine has raised €25 million in a Series B funding round in order to accelerate the deployment of its “Medication Intelligence” platform.
Using a series of AI-powered algorithms, Synapse Medicine helps doctors make better decisions on which medicines to prescribe to which patients, ultimately aiming to avoid any adverse reactions.
In order to facilitate a speedier rollout, the company also intends to use the funding to triple its workforce to 150 individuals, with recruitment drives planned for Paris, Bordeaux, Berlin, London, New York, and Tokyo over the next two years. To date, the firm has raised €35 million.
Synapse Medicine’s proprietary technology pools and organizes up-to-date drug information, ultimately helping both the general public and healthcare providers make better, more informed decisions about which drugs might have an adverse effect on which patients.
Completely independent of the pharmaceutical industry and already in use by a number of French health institutions (ANSM, ANS), hospitals (AP-HP), Hospices Civils de Lyon (public university teaching hospital), as well as other healthtech services (MesDocteurs, Teladoc Health), Synapse Medicine now plans to roll out its services to a wider audience in the U.S., Europe, and Asia via partnerships with both public and private institutions.
Read more on Tech Gist Africa:
Payhawk adds an additional $100M to an already impressive $115M Series B round
Gousto has Completed a $230M Secondary Placing led by Japanese giant SoftBank VF2
Starship Brings in $100M to Expand Autonomous Delivery in Europe and US
